Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. (2020)

First Author: Lochhead PA
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41467-020-15031-3

PubMed Identifier: 32170057

Publication URI: http://europepmc.org/abstract/MED/32170057

Type: Journal Article/Review

Volume: 11

Parent Publication: Nature communications

Issue: 1

ISSN: 2041-1723